Pfizer Inc. (PFE) — closed signal from January 6, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 6, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published January 6, 2026
Pfizer could see a short-term bounce. Announced price increases for many drugs improve the near-term story, and its dividend appeal can draw cautious buyers. The stock has fallen for a while, so wait for selling to calm before buying. This looks like a rebound trade, not a long-term recovery; policy reactions and weak follow-through are the main risks.
Primary drivers
- Planned price increases may help near-term sales and talk about revenue
- Dividend and defensive appeal can draw cautious investors
- Recent heavy selling makes a bounce more likely if it steadies
- Easy to trade size due to high daily stock volume
How it played out
PFE: target stayed just out of reach
Lyra published PFE at $25.72 on 2026-01-06 as a short-term rebound trade with expected growth of 12%. The thesis pointed to planned price increases, dividend and defensive appeal, recent heavy selling, and high daily stock volume. It also named policy reactions and weak follow-through as the main risks.
Inside the 2026-01-06 to 2026-04-06 window, PFE rose as high as $28.75 on 2026-04-02, a peak gain of 11.8%. The target was $28.80. It never got there. The stock ended at $27.83. The thesis mostly played out, but it missed the stated target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.